Co-Authors
This is a "connection" page, showing publications co-authored by MALCOLM BRENNER and MAKSIM MAMONKIN.
Connection Strength
4.066
-
Reversal of exhaustion in engineered T cells. Science. 2021 04 02; 372(6537):34-35.
Score: 0.810
-
Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies. Cancer Immunol Res. 2018 01; 6(1):47-58.
Score: 0.638
-
A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies. Blood. 2015 Aug 20; 126(8):983-92.
Score: 0.541
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 Mar 28; 143(13):1231-1241.
Score: 0.249
-
Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
Score: 0.231
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
Score: 0.224
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.193
-
Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Cancer J. 2019 May/Jun; 25(3):199-207.
Score: 0.177
-
Chimeric Antigen Receptors for T-Cell Malignancies. Front Oncol. 2019; 9:126.
Score: 0.175
-
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017 09 06; 25(9):2202-2213.
Score: 0.156
-
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood. 2017 07 20; 130(3):285-296.
Score: 0.155
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Mar 12.
Score: 0.062
-
Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs. Blood. 2022 07 07; 140(1):16-24.
Score: 0.055
-
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022 03; 24(3):282-290.
Score: 0.053
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2021 07 01; 131(13).
Score: 0.051
-
Taking T-Cell Oncotherapy Off-the-Shelf. Trends Immunol. 2021 03; 42(3):261-272.
Score: 0.050
-
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
Score: 0.049
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2019 Jul 02; 129(8):3464.
Score: 0.045
-
CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia. Mol Ther. 2019 01 02; 27(1):272-280.
Score: 0.043
-
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Rep. 2017 Oct 03; 21(1):17-26.
Score: 0.040
-
Tandem CAR T cells targeting HER2 and IL13Ra2 mitigate tumor antigen escape. J Clin Invest. 2016 08 01; 126(8):3036-52.
Score: 0.037
-
Early transduction produces highly functional chimeric antigen receptor-modified virus-specific T-cells with central memory markers: a Production Assistant for Cell Therapy (PACT) translational application. J Immunother Cancer. 2015; 3:5.
Score: 0.033